Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kanishka Monis

Interventional Pain Medicine San Antonio, TX Medical Doctor

NPI 1699911404 CMS profile 31002

5939 Babcock Rd Ste 112, Ste 112, San Antonio, TX 78240

Open in the dashboard

General payments

$12,103

386 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kanishka Monis of San Antonio, TX is reported in the CMS Open Payments database as having received $12,103 across 386 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,694 68
2024 General $2,746 85
2023 General $1,007 36
2022 General $1,607 46
2021 General $1,235 46
2020 General $1,160 36
2019 General $1,654 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kanishka Monis
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Kanishka Monis were reported at $2,694. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Kanishka Monis Interventional Pain Medicine median Middle half National median
2019 $1,654 $684 $216–$2,079 $163
2020 $1,160 $382 $122–$1,109 $114
2021 $1,235 $552 $167–$1,554 $132
2022 $1,607 $605 $187–$1,924 $149
2023 $1,007 $671 $195–$1,915 $160
2024 $2,746 $684 $206–$1,837 $164
2025 $2,694 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,255 173 payments
  2. Nevro Corp. $2,197 87 payments
  3. Medtronic, Inc. $1,746 52 payments
  4. Boston Scientific Corporation $828 17 payments
  5. Globus Medical, Inc. $634 17 payments
  6. Pfizer Inc. $203 20 payments
  7. SI-BONE, Inc. $181 2 payments
  8. Relievant Medsystems, Inc. $169 1 payment
  9. SPR Therapeutics, Inc $153 2 payments
  10. BIOTRONIK NRO, Inc. $152 3 payments
  11. Other $585 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,049 385 payments
  2. Education $55 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulator $1,691 69 payments
  2. Neuromodulation Dspsbls and Accs $1,598 40 payments
  3. PROCLAIM $1,215 26 payments
  4. Proclaim IPG $831 31 payments
  5. KYPHON EXPRESS II KYPHOPAK TRAY $726 10 payments
  6. Senza Spinal Cord Stimulator $618 16 payments
  7. OCTRODE $412 12 payments
  8. SYNCHROMEDII $399 20 payments
  9. Omnia $277 13 payments
  10. VECTRIS SURESCAN $242 12 payments
  11. Other $4,306 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,904

Median for Anesthesiology: 322

Drug cost

$104,647

Median for Anesthesiology: $8,738

Branded share of claims

75.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,625 $55,401
Oxycontin Oxycodone Hcl Brand 35 $13,752
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 397 $12,405
Hysingla Er Hydrocodone Bitartrate Brand 13 $4,642
Pregabalin Generic 80 $2,193
Oxycodone Hcl Generic 68 $2,166
Acetaminophen-Codeine Acetaminophen With Codeine Brand 86 $2,129
Fentanyl Generic 25 $2,054
Gabapentin Generic 98 $1,918
Lidocaine Generic 18 $1,728

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$401,879

Of which drugs: $3,580

Medicare patients

379

Average age 70

Services billed

26,354

226 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 25%
COPD 21%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 164 18,965 $1,889
Injection, ketorolac tromethamine, per 15 mg J1885 Office 172 1,600 $839
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 15 15 $321
Injection, methylprednisolone acetate, 40 mg J1030 Office 45 56 $213
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 125 1,817 $161
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 32 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

386 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record